TG Therapeutics, Inc. $TGTX Stock Position Reduced by Rhenman & Partners Asset Management AB

Rhenman & Partners Asset Management AB lessened its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 21.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 73,250 shares of the biopharmaceutical company’s stock after selling 19,750 shares during the period. Rhenman & Partners Asset Management AB’s holdings in TG Therapeutics were worth $2,184,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Danske Bank A S bought a new position in TG Therapeutics during the 3rd quarter worth approximately $25,000. Optiver Holding B.V. lifted its holdings in shares of TG Therapeutics by 3,485.7% in the 3rd quarter. Optiver Holding B.V. now owns 753 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 732 shares during the last quarter. Bessemer Group Inc. lifted its holdings in shares of TG Therapeutics by 117.1% in the 3rd quarter. Bessemer Group Inc. now owns 901 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 486 shares during the last quarter. Hantz Financial Services Inc. lifted its holdings in shares of TG Therapeutics by 82.7% in the 4th quarter. Hantz Financial Services Inc. now owns 1,237 shares of the biopharmaceutical company’s stock worth $37,000 after purchasing an additional 560 shares during the last quarter. Finally, EverSource Wealth Advisors LLC lifted its holdings in shares of TG Therapeutics by 86.3% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,237 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 573 shares during the last quarter. Institutional investors own 58.58% of the company’s stock.

TG Therapeutics Trading Up 3.1%

Shares of NASDAQ TGTX opened at $49.52 on Friday. The company has a market cap of $7.58 billion, a price-to-earnings ratio of 17.31 and a beta of 1.68. TG Therapeutics, Inc. has a 12-month low of $25.28 and a 12-month high of $50.41. The company has a current ratio of 5.81, a quick ratio of 5.12 and a debt-to-equity ratio of 1.28. The stock’s 50 day simple moving average is $38.38 and its 200 day simple moving average is $33.11.

TG Therapeutics (NASDAQ:TGTX) last posted its earnings results on Wednesday, May 6th. The biopharmaceutical company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.23 by ($0.11). TG Therapeutics had a net margin of 65.95% and a return on equity of 88.73%. The business had revenue of $204.92 million during the quarter, compared to analyst estimates of $200.33 million. During the same quarter in the prior year, the business earned $0.03 earnings per share. The firm’s revenue was up 69.5% compared to the same quarter last year. Equities research analysts expect that TG Therapeutics, Inc. will post 1.51 EPS for the current year.

Analyst Ratings Changes

Several analysts recently issued reports on the company. HC Wainwright reissued a “buy” rating and issued a $70.00 price target on shares of TG Therapeutics in a report on Wednesday, May 27th. Wall Street Zen downgraded TG Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, February 14th. Zacks Research raised TG Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, June 1st. Finally, Weiss Ratings raised TG Therapeutics from a “hold (c)” rating to a “hold (c+)” rating in a report on Friday, May 1st. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, TG Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $52.50.

TG Therapeutics Company Profile

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.